-
1
-
-
0035846326
-
Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent
-
Keane J, Gerhson S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alphaneutralizing agent. N Engl J Med 2001; 345: 1098-1104.
-
(2001)
N Engl J Med
, vol.345
, pp. 1098-1104
-
-
Keane, J.1
Gerhson, S.2
Wise, R.P.3
-
2
-
-
78349243317
-
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement
-
Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. Eur Respir J 2010; 36: 1185-1206.
-
(2010)
Eur Respir J
, vol.36
, pp. 1185-1206
-
-
Solovic, I.1
Sester, M.2
Gomez-Reino, J.J.3
-
3
-
-
20744440158
-
Effectiveness of recommendations to prevent reactivation of latent TB infection in patients treated with tumour necrosis factor antagonists
-
Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent TB infection in patients treated with tumour necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 1766-1772
-
-
Carmona, L.1
Gomez-Reino, J.J.2
Rodriguez-Valverde, V.3
-
4
-
-
0034091974
-
Targeted tuberculin testing and treatment of latent tuberculosis infection
-
This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement
-
Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161: S221-S247.
-
(2000)
Am J Respir Crit Care Med
, vol.161
, pp. S221-S247
-
-
-
6
-
-
84876991274
-
Evaluating the use of the interferon-c response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-A therapy: A prospective head-To-head cross-sectional study
-
Martyn-Simmons CL, Mee JB, Kirkham BW, et al. Evaluating the use of the interferon-c response to Mycobacterium tuberculosis-specific antigens in patients with psoriasis prior to antitumour necrosis factor-A therapy: A prospective head-To-head cross-sectional study. Br J Dermatol 2013; 168: 1012-1018.
-
(2013)
Br J Dermatol
, vol.168
, pp. 1012-1018
-
-
Martyn-Simmons, C.L.1
Mee, J.B.2
Kirkham, B.W.3
-
7
-
-
25444517037
-
BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-A therapy
-
Ormerod LP, Milburn HJ, Gillspie S, et al. BTS recommendations for assessing risk and for managing mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-A therapy. Thorax 2005; 60: 800-805.
-
(2005)
Thorax
, vol.60
, pp. 800-805
-
-
Ormerod, L.P.1
Milburn, H.J.2
Gillspie, S.3
-
8
-
-
67650116366
-
Novel screening tools for latent tuberculosis: Time to leave an old friend?
-
Villiger PM, Zellweger JP, Moller B. Novel screening tools for latent tuberculosis: Time to leave an old friend? Curr Opin Rheumatol 2009; 21: 238-243.
-
(2009)
Curr Opin Rheumatol
, vol.21
, pp. 238-243
-
-
Villiger, P.M.1
Zellweger, J.P.2
Moller, B.3
-
9
-
-
67349134712
-
European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease
-
Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3: 47-91.
-
(2009)
J Crohns Colitis
, vol.3
, pp. 47-91
-
-
Rahier, J.F.1
Ben-Horin, S.2
Chowers, Y.3
-
10
-
-
0026541562
-
A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong
-
Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research Council
-
Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
-
(1992)
Am Rev Respir Dis
, vol.145
, pp. 36-41
-
-
-
11
-
-
48749127991
-
Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update.
-
Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008; 149: 177-184.
-
(2008)
Ann Intern Med
, vol.149
, pp. 177-184
-
-
Pai, M.1
Zwerling, A.2
Menzies, D.3
-
12
-
-
84875576458
-
Yield and cost effectiveness of my cobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF therapy
-
Greveson K, Goodhand J, Capocci S, et al. Yield and cost effectiveness of my cobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNF therapy. J Crohns Colitis 2013; 7: 412-418.
-
(2013)
J Crohns Colitis
, Issue.7
, pp. 412-418
-
-
Greveson, K.1
Goodhand, J.2
Capocci, S.3
-
13
-
-
84884556119
-
Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculous chemoprophylaxis prior to commencement of TNF-A antagonist therapy
-
Singanayagam A, Manalan K, Sridhar S, et al. Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculous chemoprophylaxis prior to commencement of TNF-A antagonist therapy. Thorax 2013; 68: 955-961.
-
(2013)
Thorax
, vol.68
, pp. 955-961
-
-
Singanayagam, A.1
Manalan, K.2
Sridhar, S.3
-
14
-
-
84896477367
-
Tuberculosis elimination: Theory and practice in Europe
-
D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: Theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
-
(2014)
Eur Respir J
, vol.43
, pp. 1410-1420
-
-
D'Ambrosio, L.1
Dara, M.2
Tadolini, M.3
-
15
-
-
77949477575
-
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)
-
Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-528.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 522-528
-
-
Dixon, W.G.1
Hyrich, K.L.2
Watson, K.D.3
|